response or better were 62.7% vs 16.4% and 59.1% vs 31.3%, respectively. The safety population included 131 pts with prior BORT (67 PVd; 64 Vd) and 90 pts without prior BORT (44 PVd; 46 Vd). The most common hematologic grade 3/4 treatmentemergent AEs with PVd vs Vd were neutropenia (44.8% vs 10.9% prior BORT, 22.7% vs 8.7% no prior BORT) and thrombocytopenia (23.9% vs 26.6% prior BORT, 13.6% vs 13.0% no prior BORT). Grade 3/4 infections occurred in 26.9% vs 15.6% (pneumonia 7.5% vs 4.7%) in pts with prior BORT and 31.8% vs 15.2% (pneumonia 11.4% vs 6.5%) in pts without prior BORT. Grade 3/4 peripheral sensory neuropathy occurred in 10.4% vs 0% and 6.8% vs 8.7%, respectively. Conclusion: After 1 prior LOT, PVd significantly reduced the risk of progression or death by 53% vs Vd in pts previously treated with BORT. Second-line PVd also significantly improved ORR, regardless of prior BORT treatment, and led to deeper responses vs Vd. Data demonstrate that PVd is an effective second-line treatment in pts who previously received BORT and LEN. The safety of PVd was consistent with the known profiles of each agent.
Background: High-risk cytogenetic abnormalities (HR CAs) negatively impact on the prognosis of patients (pts) with multiple myeloma (MM). ICARIA-MM was a randomized, open-label, activecontrolled, multicenter phase 3 study that investigated the anti-CD38 monoclonal antibody isatuximab (Isa) in combination with pomalidomide and dexamethasone (Pd) in pts with relapsed/refractory MM (RRMM) who had received 2 prior lines of therapy (NCT02990338). Progression free survival (PFS) was significantly improved with Isa-Pd vs Pd (11.5 vs 6.5 months; hazard ratio [HR] 0.60 [95% confidence interval (CI) 0.44e0.81]). This subgroup analysis of ICARIA-MM examined efficacy in pts with HR CAs. Methods: Pts were considered of high cytogenetic risk if they had 1 del(17p), t(4;14), or t(14;16) abnormalities at study entry. Cytogenetic analysis was performed by a central laboratory using cut-offs of 50% for del(17p), 30% for t(4;14) and t(14;16). Isa (10 mg/kg IV) was given on days 1, 8, 15, and 22 (cycle 1), and days 1 and 15 in subsequent 28-day cycles. All pts received pomalidomide 4 mg on days 1 to 21 of each cycle and dexamethasone 40 mg (20 mg for pts 75 years old) on days 1, 8, 15, and 22 of each cycle. The primary endpoint was PFS in the intent to treat (ITT) population. Results: In the ITT population, 24/154 (15.6%) pts in the Isa-Pd group and 36/ 153 (23.5%) in the Pd group had 1 HR CA (high-risk pts). In the Isa-Pd and Pd arms, respectively, there were 14 and 23 pts with del(17p); 12 and 14 pts with t(4;14), and 1 and 4 pts with t(14;16). A similar benefit of treatment on PFS was observed for high-risk pts (Isa-Pd 7.5 vs Pd 3.7 months; HR 0.66 [95% CI, 0.33e1.28]) and standard-risk pts (Isa-Pd 11.6 [n¼103] vs Pd 7.4 months [n¼78]; HR 0.62 [95% CI 0.42e0.93]). Among pts with del(17p) in the Isa-Pd and Pd arms, respectively, median PFS was 9.1 and 7.4 months (HR 0.76 [95% CI 0.30e1.92]), and for pts with t(4,14), median PFS was 7.5 and 2.8 months (HR 0.49 [95% CI, 0.19e1.31] ). Overall response rate (ORR) in high-risk pts (Isa-Pd 50.0% vs Pd 16.7%) had an odds ratio (OR) of 5.00 (95% CI, 1.33e19.79) compared with standard-risk pts (Isa-Pd 65.0% vs Pd 42.3%) with an OR of 2.54 (95% CI, 1.33e4.86). Very good partial response or better in high risk patients (Isa-Pd 29.2% vs Pd 2.8%) had an odds ratio of 14.41 [95% CI, 1.57e667.48]) compared with standard-risk pts (Isa-Pd 32.0% vs Pd 9.0%) with an OR of 4.78 [95% CI, 1.90e13.57]). In the safety population, grade 3 treatment-emergent adverse events were reported in 22/23 (96%) and 23/34 (68%) high-risk pts, and 88/103 (85%) and 58/76 (76%) standard-risk pts, respectively. Few pts discontinued Isa-Pd treatment due to adverse events (high-risk, 9%; standard-risk, 7%). Conclusion: The addition of Isa to Pd improved PFS and ORR in pts with RRMM and benefit was maintained among pts with high-risk cytogenetics. 
